1. Home
  2. GNPX vs ACON Comparison

GNPX vs ACON Comparison

Compare GNPX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$1.35

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Aclarion Inc.

ACON

Aclarion Inc.

HOLD

Current Price

$3.56

Market Cap

3.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
ACON
Founded
2009
2008
Country
United States
United States
Employees
N/A
6
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
GNPX
ACON
Price
$1.35
$3.56
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
272.2K
50.5K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$87.22
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$2.34
52 Week High
$12.97
$12.03

Technical Indicators

Market Signals
Indicator
GNPX
ACON
Relative Strength Index (RSI) 25.92 57.98
Support Level $0.18 $3.03
Resistance Level $2.12 $3.56
Average True Range (ATR) 0.12 0.24
MACD -0.05 0.04
Stochastic Oscillator 6.57 85.00

Price Performance

Historical Comparison
GNPX
ACON

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Share on Social Networks: